Nictavi LLC

Nictavi LLC FDA Registration #3017733452 Operator #10079434, MBE, SB, Our first product, the patented, novel, Tarsus Eyelid Patch, is a comfortable, effective method of eye closure to retain moisture, reduce the occurrence and heal epithelial or corneal surface defects, and enhance the effectiveness of eye medicines. This reducing doctor visits, surgeries, pain, irritation, and the chance of infections, preserving people's sight and improving their quality of life. There are currently NO COMFORTABLE, effective products designed for the Corneal Care, Eye Closure / Occlusion, and Ocular Therapeutics Markets. There is a need for a comfortable eye closure device and method to treat Nocturnal Lagophthalmos. Our product can be worn during sleep to address Noctural Lagophthalmos (the cause) and prevent corneal defects or damage, (the symptoms). Nocturnal Lagophthalmos is the inability to close the eyelids during sleep. It may reduce the quality of sleep, cause exposure-related symptoms or, if severe, cause corneal damage (exposure keratopathy). The degree of Lagophthalmos can be minor (obscure Lagophthalmos), or quite obvious. In our early stages, we are implementing a Lean Startup Business Model Design starting with Ophthalmologists. The doctors and their patients will be the early adopters and early influencers creating initial awareness and demand for our product. We have a business plan that will be implemented after we acquire evidence, and validation from markets and we are ready to scale to the next level. Then the Tarsus Patch will be sold Over The Counter. We will inform markets of our product and method through select nationwide promotion and advertising. The resulting public awareness will build our market. We will be educating the public to the healing practice, and the eye health benefits of eye closure, for those with applicable issues and their caregivers and inform them there is now a product and method for their need.